Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Slightly Bullish +25

Is Zimmer Biomet Stock Underperforming the S&P 500? - Barchart.com

🏢 Zimmer Biomet is a $17.1 billion market cap leader in orthopedic implants and digital solutions operating globally.

📉 Stock price has slipped 18.2% from its 52-week high of $108.29 achieved on Aug. 26, 2025.

📊 ZBH is down 4.3% over the past three months while the S&P 500 rose 11.4% during the same period.

📈 Shares recently climbed back above their 50-day moving average after trading below the 200-day average since March.

💰 Analysts hold a consensus 'Hold' rating with a mean price target of $98.24, a 10.9% premium to current prices.

🆚 The stock has outperformed peer Medtronic (MDT), which declined 16.5% on a YTD basis.

Bullish Signals
  • The company operates in more than 100 countries with a broad portfolio of hip, knee, shoulder, and trauma implants.
  • ZBH has outperformed its major peer Medtronic (MDT), which has declined significantly over the past year.
  • Shares have recently shown signs of technical recovery by climbing back above the 50-day moving average.
  • The mean analyst price target of $98.24 suggests a potential upside of approximately 10.9% from current levels.
Risk Factors
  • The stock has slipped 18.2% from its 52-week high, indicating significant recent weakness.
  • Investors are growing concerned about the company's sluggish growth profile and modest revenue gains.
  • ZBH has trailed the S&P 500 Index significantly over the past year with a muted sales outlook.
Full Analysis
Zimmer Biomet Holdings, Inc. (ZBH) is a large-cap medical technology company with a market capitalization of $17.1 billion, specializing in orthopedic implants and surgical products across over 100 countries. The company benefits from an aging demographic driving demand for mobility solutions and maintains strong relationships with hospitals and surgeons. Despite its solid fundamentals, ZBH stock has underperformed the broader market recently. Shares have slipped 18.2% from their 52-week high of $108.29 and are down 4.3% over the past three months compared to the S&P 500's 11.4% rise. Investors appear concerned about the company's sluggish growth profile, modest revenue gains, and muted sales outlook. Technically, ZBH shares have traded below their 200-day moving average since early March but recently regained momentum by climbing back above the 50-day moving average. Analysts maintain a consensus 'Hold' rating with a mean price target of $98.24, representing a 10.9% premium to current levels. The stock has outperformed peer Medtronic (MDT) over the past year.